Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin: A randomized, 52-week, double-blind, active-controlled noninferiority trial

OBJECTIVE: Although initially effective, sulfonylureas are associated with poor glycemic durability, weight gain, and hypoglycemia. Dapagliflozin, a selective inhibitor of sodium-glucose cotransporter 2 (SGLT2), reduces hyperglycemia by increasing urinary glucose excretion independent of insulin and...

Descripción completa

Detalles Bibliográficos
Autores principales: Nauck, Michael A., Del Prato, Stefano, Meier, Juris J., Durán-García, Santiago, Rohwedder, Katja, Elze, Martina, Parikh, Shamik J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2011
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3161265/
https://www.ncbi.nlm.nih.gov/pubmed/21816980
http://dx.doi.org/10.2337/dc11-0606

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3161265/
https://www.ncbi.nlm.nih.gov/pubmed/21816980
http://dx.doi.org/10.2337/dc11-0606

Ejemplares similares